{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T18:00:15Z","timestamp":1779386415772,"version":"3.53.1"},"reference-count":97,"publisher":"Institute of Physiology of the Czech Academy of Sciences","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Physiol Res"],"published-print":{"date-parts":[[2025,4,30]]},"abstract":"<jats:p>Bruton\u2019s tyrosine kinase (BTK) is a crucial part of the B-cell receptor signaling pathway that has been extensively studied in various types of malignancies. Recent studies have extended our knowledge on its role in metabolism as well as neurological disorders. It may play an important role in the pathophysiology of neurological diseases, such as multiple sclerosis, Alzheimer\u2019s disease, brain injury, and several others. Activation of inflammasomes, mainly NLRP3, is one of the core mechanisms by which it promotes inflammation in the brain related to aging and diseases. In this paper, we provide an overview of the less explored roles of BTK in several brain diseases and discuss the potential of its inhibition to become a therapeutic target for neurological diseases.<\/jats:p>","DOI":"10.33549\/physiolres.935494","type":"journal-article","created":{"date-parts":[[2025,5,18]],"date-time":"2025-05-18T20:07:32Z","timestamp":1747598852000},"page":"233-248","source":"Crossref","is-referenced-by-count":4,"title":["Bruton\u2019s Tyrosine Kinase: A Potential Novel Target for Neurological Disorders"],"prefix":"10.33549","author":[{"given":"D","family":"Das","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Greco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Michali\u010dkov\u00e1","sequence":"additional","affiliation":[{"name":"Institute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic. E-mail: danica.michalickova@lf1.cuni.cz"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O","family":"Slana\u0159","sequence":"additional","affiliation":[{"name":"Institute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic. ondrej.slanar@lf1.cuni.cz"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"19169","reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"Wu J, Liu C, Tsui ST, et al. Second-generation inhibitors of Bruton tyrosine kinase. J Hematol Oncol. 2016;9(1):80. https:\/\/doi.org\/10.1186\/s13045-016-0313-y","DOI":"10.1186\/s13045-016-0313-y"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Estupi\u00f1\u00e1n HY, Bergl\u00f6f A, Zain R, et al. Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects. Front Cell Dev Biol. 2021;9:630942. https:\/\/doi.org\/10.3389\/fcell.2021.630942","DOI":"10.3389\/fcell.2021.630942"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Jongstra-Bilen J, Puig Cano A, Hasija M, et al. Dual Functions of Bruton's Tyrosine kinase and tec kinase during fc\u03b3 receptor-induced signaling and phagocytosis. J Immunol 2008;181(1):288-298. https:\/\/doi.org\/10.4049\/jimmunol.181.1.288","DOI":"10.4049\/jimmunol.181.1.288"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Ringheim GE, Wampole M, Oberoi K. Bruton's Tyrosine Kinase (BTK) Inhibitors and Autoimmune Diseases: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures. Front Immunol. 2021;12:662223. https:\/\/doi.org\/10.3389\/fimmu.2021.662223","DOI":"10.3389\/fimmu.2021.662223"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Montalban X, Arnold DL, Weber MS, et al. Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis. N Engl J Med. 2019;380(25):2406-2417. https:\/\/doi.org\/10.1056\/NEJMoa1901981","DOI":"10.1056\/nejmoa1901981"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Smith CIE, Burger JA. Resistance Mutations to BTK Inhibitors Originate From the NF-\u03baB but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway. Front Immunol. 2021;12:689472. https:\/\/doi.org\/10.3389\/fimmu.2021.689472","DOI":"10.3389\/fimmu.2021.689472"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Wen T, Wang J, Shi Y, et al. Inhibitors targeting Bruton's tyrosine kinase in cancers: drug development advances. Leukemia. 2021;35(2):312-332. https:\/\/doi.org\/10.1038\/s41375-020-01072-6","DOI":"10.1038\/s41375-020-01072-6"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Tasso B, Spallarossa A, Russo E, et al. The Development of BTK Inhibitors: A Five-Year Update. Molecules. 2021;26(23):7411. https:\/\/doi.org\/10.3390\/molecules26237411","DOI":"10.3390\/molecules26237411"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Dolgin E. BTK blockers make headway in multiple sclerosis. Nat Biotechnol. 2021;39(1):3-5. https:\/\/doi.org\/10.1038\/s41587-019-0381-y, https:\/\/doi.org\/10.1038\/s41587-020-00790-7, https:\/\/doi.org\/10.1038\/ d41587-021-00025-3","DOI":"10.1038\/s41587-020-00790-7"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Zhang D, Gong H, Meng F. Recent Advances in BTK Inhibitors for the Treatment of Inflammatory and Autoimmune Diseases. Molecules. 2021;26(16):4907. https:\/\/doi.org\/10.3390\/molecules26164907","DOI":"10.3390\/molecules26164907"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Woyach JA, Furman RR, Liu T-M, et al. Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib. N Engl J Med. 2014;370(24):2286-2294. https:\/\/doi.org\/10.1056\/NEJMoa1400029","DOI":"10.1056\/NEJMoa1400029"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Young WB, Barbosa J, Blomgren P, et al. Discovery of highly potent and selective Bruton's tyrosine kinase inhibitors: Pyridazinone analogs with improved metabolic stability. Bioorg Med Chem Lett. 2016;26(2):575-579. https:\/\/doi.org\/10.1016\/j.bmcl.2015.11.076","DOI":"10.1016\/j.bmcl.2015.11.076"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Noy A, de Vos S, Thieblemont C, et al. Targeting Bruton tyrosine kinase with ibrutinib in relapsed\/refractory marginal zone lymphoma. Blood. 2017;129(16):2224-2232. https:\/\/doi.org\/10.1182\/blood-2016-10-747345","DOI":"10.1182\/blood-2016-10-747345"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A. 2010;107(29):13075-13080. https:\/\/doi.org\/10.1073\/pnas.1004594107","DOI":"10.1073\/pnas.1004594107"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507-516. https:\/\/doi.org\/10.1056\/NEJMoa1306220","DOI":"10.1056\/NEJMoa1306220"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32-42. https:\/\/doi.org\/10.1056\/NEJMoa1215637","DOI":"10.1056\/nejmoa1215637"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Treon SP, Tripsas CK, Meid K, et al. Ibrutinib in previously treated Waldenstr\u00f6m's macroglobulinemia. N Engl J Med. 2015;372(15):1430-1440. https:\/\/doi.org\/10.1056\/NEJMoa1501548","DOI":"10.1056\/NEJMoa1501548"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Miklos D, Cutler CS, Arora M, et al. Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. Blood. 2017;130(21):2243-2250. https:\/\/doi.org\/10.1182\/blood-2017-07-793786","DOI":"10.1182\/blood-2017-07-793786"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Levade M, David E, Garcia C, et al. Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions. Blood. 2014;124(26):3991-3995. https:\/\/doi.org\/10.1182\/blood-2014-06-583294","DOI":"10.1182\/blood-2014-06-583294"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Shanafelt TD, Wang XV, Kay NE, et al. Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia. N Engl J Med. 2019;381(5):432-443. https:\/\/doi.org\/10.1056\/NEJMoa1817073","DOI":"10.1056\/NEJMoa1817073"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Munir T, Brown JR, O'Brien S, et al. Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol. 2019;94(12):1353-1363. https:\/\/doi.org\/10.1002\/ajh.25638","DOI":"10.1002\/ajh.25638"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Nicolson PLR, Hughes CE, Watson S, et al. Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI. Haematologica. 2018;103(12):2097-2108. https:\/\/doi.org\/10.3324\/haematol.2018.193391","DOI":"10.3324\/haematol.2018.193391"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Tam CS, Opat S, D'Sa S, et al. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: the ASPEN study. Blood. 2020;136(18):2038-2050. https:\/\/doi.org\/10.1182\/blood.2020006844","DOI":"10.1182\/blood.2021010665"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Sharman JP, Egyed M, Jurczak W, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet. 2020;395(10232):1278-1291. https:\/\/doi.org\/10.1016\/S0140-6736(20)30262-2","DOI":"10.3410\/f.737782285.793582414"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Ghia P, Pluta A, Wach M, et al. ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. J Clin Oncol. 2020;38(25):2849-2861. https:\/\/doi.org\/10.1200\/JCO.19.03355","DOI":"10.1200\/jco.19.03355"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Hillmen P, Eichhorst B, Brown JR, et al. Zanubrutinib Versus Ibrutinib in Relapsed\/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial. JCO. 2023;41(5):1035-1045. https:\/\/doi.org\/10.1200\/JCO.22.00510","DOI":"10.1200\/jco.22.00510"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Bye AP, Unsworth AJ, Desborough MJ, et al. Severe platelet dysfunction in NHL patients receiving ibrutinib is absent in patients receiving acalabrutinib. Blood Adv. 2017;1(26):2610-2623. https:\/\/doi.org\/10.1182\/bloodadvances.2017011999","DOI":"10.1182\/bloodadvances.2018028944"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Ma B, Metrick CM, Gu C, et al. Optimization of a novel piperazinone series as potent selective peripheral covalent BTK inhibitors. Bioorganic & Medicinal Chemistry Letters. 2022;60:128549. https:\/\/doi.org\/10.1016\/j.bmcl.2022.128549","DOI":"10.1016\/j.bmcl.2022.128549"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Elamin G, Aljoundi A, Alahmdi MI, et al. Battling BTK mutants with noncovalent inhibitors that overcome Cys481 and Thr474 mutations in Waldenstr\u00f6m macroglobulinemia therapy: structural mechanistic insights on the role of fenebrutinib. J Mol Model. 2022;28(11):355. https:\/\/doi.org\/10.1007\/s00894-022-05345-y","DOI":"10.1007\/s00894-022-05345-y"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Brullo C, Villa C, Tasso B, et al. Btk Inhibitors: A Medicinal Chemistry and Drug Delivery Perspective. Int J Mol Sci. 2021;22(14):7641. https:\/\/doi.org\/10.3390\/ijms22147641","DOI":"10.3390\/ijms22147641"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Dickson EJ, Hille B. Understanding phosphoinositides: rare, dynamic, and essential membrane phospholipids. Biochemical Journal. 2019;476(1):1-23. https:\/\/doi.org\/10.1042\/BCJ20180022","DOI":"10.1042\/bcj20180022"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Solvason N, Wu WW, Kabra N, et al. Transgene Expression of bcl-xL Permits Anti-immunoglobulin (Ig)-induced Proliferation in xid B Cells. Journal of Experimental Medicine. 1998;187(7):1081-1091. https:\/\/doi.org\/10.1084\/jem.187.7.1081","DOI":"10.1084\/jem.187.7.1081"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Schaeffer EM, Debnath J, Yap G, et al. Requirement for Tec Kinases Rlk and Itk in T Cell Receptor Signaling and Immunity. Science. 1999;284(5414):638-641. https:\/\/doi.org\/10.1126\/science.284.5414.638","DOI":"10.1126\/science.284.5414.638"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Smith CIE, Islam TC, Mattsson PT, et al. The Tec family of cytoplasmic tyrosine kinases: mammalian Btk, Bmx, Itk, Tec, Txk and homologs in other species. Bioessays. 2001;23(5):436-446. https:\/\/doi.org\/10.1002\/bies.1062","DOI":"10.1002\/bies.1062"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Basile N, Danielian S, Oleastro M, et al. Clinical and Molecular Analysis of 49 Patients With X-linked Agammaglobulinemia From A Single Center in Argentina. J Clin Immunol. 2009;29(1):123-129. https:\/\/doi.org\/10.1007\/s10875-008-9227-y","DOI":"10.1007\/s10875-008-9227-y"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"V\u00e4liaho J, Smith CIE, Vihinen M. BTKbase: the mutation database for X-linked agammaglobulinemia. Hum Mutat. 2006;27(12):1209-1217. https:\/\/doi.org\/10.1002\/humu.20410","DOI":"10.1002\/humu.20410"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Rawlings DJ, Saffran DC, Tsukada S, et al. Mutation of Unique Region of Bruton's Tyrosine Kinase in Immunodeficient XID Mice. Science. 1993;261(5119):358-361. https:\/\/doi.org\/10.1126\/science.8332901","DOI":"10.1126\/science.8332901"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Cancro MP, Sah AP, Levy SL, et al. xid mice reveal the interplay of homeostasis and Bruton's tyrosine kinase-mediated selection at multiple stages of B cell development. International Immunology. 2001;13(12):1501-1514. https:\/\/doi.org\/10.1093\/intimm\/13.12.1501","DOI":"10.1093\/intimm\/13.12.1501"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Torke S, Pretzsch R, H\u00e4usler D, et al. Inhibition of Bruton's tyrosine kinase interferes with pathogenic B-cell development in inflammatory CNS demyelinating disease. Acta Neuropathol. 2020;140(4):535-548. https:\/\/doi.org\/10.1007\/s00401-020-02204-z","DOI":"10.1007\/s00401-020-02204-z"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Middendorp S, Dingjan GM, Hendriks RW. Impaired Precursor B Cell Differentiation in Bruton's Tyrosine Kinase-Deficient Mice. The Journal of Immunology. 2002;168(6):2695-2703. https:\/\/doi.org\/10.4049\/jimmunol.168.6.2695","DOI":"10.4049\/jimmunol.168.6.2695"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Cariappa A, Tang M, Parng C, et al. The Follicular versus Marginal Zone B Lymphocyte Cell Fate Decision Is Regulated by Aiolos, Btk, and CD21. Immunity. 2001;14(5):603-615. https:\/\/doi.org\/10.1016\/S1074-7613(01)00135-2","DOI":"10.1016\/s1074-7613(01)00135-2"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"L\u00fcnemann JD, Malhotra S, Shinohara ML, et al. Targeting Inflammasomes to Treat Neurological Diseases. Ann Neurol. 2021;90(2):177-188. https:\/\/doi.org\/10.1002\/ana.26158","DOI":"10.1002\/ana.26158"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Rip J, Van Der Ploeg EK, Hendriks RW, et al. The Role of Bruton's Tyrosine Kinase in Immune Cell Signaling and Systemic Autoimmunity. Crit Rev Immunol. 2018;38(1):17-62. https:\/\/doi.org\/10.1615\/CritRevImmunol.2018025184","DOI":"10.1615\/critrevimmunol.2018025184"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"DiSabato D, Quan N, Godbout JP. Neuroinflammation: The Devil is in the Details. J Neurochem. 2016;139(Suppl 2):136-153. https:\/\/doi.org\/10.1111\/jnc.13607","DOI":"10.1111\/jnc.13607"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"Chen F, Ghosh A, Lin J, et al. 5-lipoxygenase pathway and its downstream cysteinyl leukotrienes as potential therapeutic targets for Alzheimer's disease. Brain Behav Immun 2020;88:844-855. https:\/\/doi.org\/10.1016\/j.bbi.2020.03.022","DOI":"10.1016\/j.bbi.2020.03.022"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"Zheng Z-H, Tu J-L, Li X-H, et al. Neuroinflammation induces anxiety- and depressive-like behavior by modulating neuronal plasticity in the basolateral amygdala. Brain Behav Immun 2021;91:505-518. https:\/\/doi.org\/10.1016\/j.bbi.2020.11.007","DOI":"10.1016\/j.bbi.2020.11.007"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"Subramanian J, Savage JC, Tremblay M-\u00c8. Synaptic Loss in Alzheimer's disease: mechanistic insights provided by two-photon in vivo imaging of transgenic mouse models. Frontiers in Cellular Neuroscience [Internet]. 2020 [cited 2023 Mar 6];14. https:\/\/doi.org\/10.3389\/fncel.2020.592607","DOI":"10.3389\/fncel.2020.592607"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"Zhang Y, Chen K, Sloan SA, et al. An RNA-Sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J Neurosci. 2014;34(36):11929-11947. https:\/\/doi.org\/10.1523\/JNEUROSCI.1860-14.2014","DOI":"10.1523\/jneurosci.1860-14.2014"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"Zhang Y, Sloan SA, Clarke LE, et al. Purification and characterization of progenitor and mature human astrocytes reveals transcriptional and functional differences with mouse. Neuron. 2016;89(1):37-53. https:\/\/doi.org\/10.1016\/j.neuron.2015.11.013","DOI":"10.1016\/j.neuron.2015.11.013"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"Keaney J, Gasser J, Gillet G, et al. Inhibition of Bruton's tyrosine kinase modulates microglial phagocytosis: therapeutic implications for Alzheimer's disease. J Neuroimmune Pharmacol. 2019;14(3):448-461. https:\/\/doi.org\/10.1007\/s11481-019-09839-0","DOI":"10.1007\/s11481-019-09839-0"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"Lee H, Jeon SG, Kim J, et al. Ibrutinib modulates A\u03b2\/tau pathology, neuroinflammation, and cognitive function in mouse models of Alzheimer's disease. Aging Cell [Internet]. 2021 [cited 2023 Apr 15];20(3). https:\/\/doi.org\/10.1111\/acel.13332","DOI":"10.1111\/acel.13953"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"Dybowski S, Torke S, Weber MS. Targeting B cells and microglia in multiple sclerosis with bruton tyrosine kinase inhibitors: a review. JAMA Neurol. 2023;80(4):404. https:\/\/doi.org\/10.1001\/jamaneurol.2022.5332","DOI":"10.1001\/jamaneurol.2022.5332"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"Fusco R, Siracusa R, Genovese T, et al. Focus on the role of NLRP3 inflammasome in diseases. Int J Mol Sci. 2020;21(12):4223. https:\/\/doi.org\/10.3390\/ijms21124223","DOI":"10.3390\/ijms21124223"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"Guo H, Callaway JB, Ting JP-Y. Inflammasomes: mechanism of action, role in disease, and therapeutics. Nat Med. 2015;21(7):677-687. https:\/\/doi.org\/10.1038\/nm.3893","DOI":"10.1038\/nm.3893"},{"key":"ref54","doi-asserted-by":"publisher","unstructured":"Youm Y-H, Grant RW, McCabe LR, et al. Canonical Nlrp3 inflammasome links systemic low grade inflammation to functional decline in aging. Cell Metab. 2013;18(4):519-532. https:\/\/doi.org\/10.1016\/j.cmet.2013.09.010","DOI":"10.1016\/j.cmet.2013.09.010"},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"Jin L, Mo Y, Yue E-L, et al. Ibrutinib ameliorates cerebral ischemia\/reperfusion injury through autophagy activation and PI3K\/Akt\/mTOR signaling pathway in diabetic mice. Bioengineered. 2021;12(1):7432-7445. https:\/\/doi.org\/10.1080\/21655979.2021.1974810","DOI":"10.1080\/21655979.2021.1974810"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"Ito M, Shichita T, Okada M, et al. Bruton's tyrosine kinase is essential for NLRP3 inflammasome activation and contributes to ischaemic brain injury. Nat Commun. 2015;6:7360. https:\/\/doi.org\/10.1038\/ncomms8360","DOI":"10.1038\/ncomms8360"},{"key":"ref57","doi-asserted-by":"publisher","unstructured":"Bittner ZA, Liu X, Mateo Tortola M, et al. BTK operates a phospho-tyrosine switch to regulate NLRP3 inflammasome activity. J Exp Med. 2021;218(11):e20201656. https:\/\/doi.org\/10.1084\/jem.20201656","DOI":"10.1242\/prelights.23060"},{"key":"ref58","doi-asserted-by":"publisher","unstructured":"Ghosh S, Mohammed Z, Singh I. Pharmacological Inhibition of BTK reduces neuroinflammation and stress induced anxiety in vivo [Internet]. bioRxiv; 2021 [cited 2023 Mar 6]. p. 2021.01.11.426241. Available from: https:\/\/www.biorxiv.org\/content\/10.1101\/2021.01.11.426241v1. https:\/\/doi.org\/10.1101\/2021.01.11.426241","DOI":"10.1101\/2021.01.11.426241"},{"key":"ref59","doi-asserted-by":"publisher","unstructured":"Franke M, Bieber M, Kraft P, et al. The NLRP3 inflammasome drives inflammation in ischemia\/reperfusion injury after transient middle cerebral artery occlusion in mice. Brain Behav Immun 2021;92:221-231. https:\/\/doi.org\/10.1016\/j.bbi.2020.12.009","DOI":"10.1016\/j.bbi.2020.12.009"},{"key":"ref60","doi-asserted-by":"publisher","unstructured":"Ghosh S, Mohammed Z, Singh I. Bruton's tyrosine kinase drives neuroinflammation and anxiogenic behavior in mouse models of stress. J Neuroinflammation. 2021;18(1):289. https:\/\/doi.org\/10.1186\/s12974-021-02322-9","DOI":"10.1186\/s12974-021-02322-9"},{"key":"ref61","doi-asserted-by":"publisher","unstructured":"Cui Y, Yu H, Bu Z, et al. Focus on the Role of the NLRP3 Inflammasome in Multiple Sclerosis: Pathogenesis, Diagnosis, and Therapeutics. Front Mol Neurosci. 2022;15:894298. https:\/\/doi.org\/10.3389\/fnmol.2022.894298","DOI":"10.3389\/fnmol.2022.894298"},{"key":"ref62","doi-asserted-by":"publisher","unstructured":"Hanslik KL, Ulland TK. The Role of Microglia and the Nlrp3 Inflammasome in Alzheimer's Disease. Front Neurol. 2020;11:570711. https:\/\/doi.org\/10.3389\/fneur.2020.570711","DOI":"10.3389\/fneur.2020.570711"},{"key":"ref63","doi-asserted-by":"publisher","unstructured":"Lassmann H. Pathogenic mechanisms associated with different clinical courses of multiple sclerosis. Front Immunol. 2018;9:3116. https:\/\/doi.org\/10.3389\/fimmu.2018.03116","DOI":"10.3389\/fimmu.2018.03116"},{"key":"ref64","doi-asserted-by":"publisher","unstructured":"Milo R. Therapies for multiple sclerosis targeting B cells. Croat Med J. 2019;60(2):87-98. https:\/\/doi.org\/10.3325\/cmj.2019.60.87","DOI":"10.3325\/cmj.2019.60.87"},{"key":"ref65","doi-asserted-by":"publisher","unstructured":"Touil H, Li R, Zuroff L, et al. Cross-talk between B cells, microglia and macrophages, and implications to central nervous system compartmentalized inflammation and progressive multiple sclerosis. eBioMedicine. 2023;96:104789. https:\/\/doi.org\/10.1016\/j.ebiom.2023.104789","DOI":"10.1016\/j.ebiom.2023.104789"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"Comi G, Bar-Or A, Lassmann H, et al. Role of B cells in multiple sclerosis and related disorders. Ann Neurol. 2021;89(1):13-23. https:\/\/doi.org\/10.1002\/ana.25927","DOI":"10.1002\/ana.25927"},{"key":"ref67","doi-asserted-by":"publisher","unstructured":"Li R, Tang H, Burns JC, et al. BTK inhibition limits B-cell-T-cell interaction through modulation of B-cell metabolism: implications for multiple sclerosis therapy. Acta Neuropathol. 2022;143(4):505-521. https:\/\/doi.org\/10.1007\/s00401-022-02411-w","DOI":"10.1007\/s00401-022-02411-w"},{"key":"ref68","doi-asserted-by":"publisher","unstructured":"Pellerin K, Rubino SJ, Burns JC, et al. MOG autoantibodies trigger a tightly-controlled FcR and BTK-driven microglia proliferative response. Brain. 2021;144(8):2361-2374. https:\/\/doi.org\/10.1093\/brain\/awab231","DOI":"10.1093\/brain\/awab231"},{"key":"ref69","doi-asserted-by":"publisher","unstructured":"Hopkins BT, Bame E, Bajrami B, et al. Discovery and preclinical characterization of BIIB091, a reversible, selective BTK inhibitor for the treatment of multiple sclerosis. J Med Chem. 2022;65(2):1206-1224. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c00926","DOI":"10.1021\/acs.jmedchem.1c00926.s001"},{"key":"ref70","doi-asserted-by":"publisher","unstructured":"Saez-Atienzar S, Masliah E. Cellular senescence and Alzheimer disease: the egg and the chicken scenario. Nat Rev Neurosci. 2020;21(8):433-444. https:\/\/doi.org\/10.1038\/s41583-020-0325-z","DOI":"10.1038\/s41583-020-0325-z"},{"key":"ref71","doi-asserted-by":"crossref","unstructured":"Peters R. Ageing and the brain. Postgrad Med J. 2006;82(964):84-88. https:\/\/doi.org\/10.1136\/pgmj.2005.036665","DOI":"10.1136\/pgmj.2005.036665"},{"key":"ref72","doi-asserted-by":"publisher","unstructured":"Ekpenyong-Akiba AE, Poblocka M, Althubiti M, et al. Amelioration of age-related brain function decline by Bruton's tyrosine kinase inhibition. Aging Cell. 2020;19(1):e13079. https:\/\/doi.org\/10.1111\/acel.13079","DOI":"10.1111\/acel.13079"},{"key":"ref73","doi-asserted-by":"publisher","unstructured":"Mendez MF. The Relationship Between Anxiety and Alzheimer's Disease. J Alzheimer's Dis Rep 2021;5(1):171. https:\/\/doi.org\/10.3233\/ADR-219003 https:\/\/doi.org\/10.3233\/ADR-210294","DOI":"10.3233\/adr-210294"},{"key":"ref74","doi-asserted-by":"publisher","unstructured":"Limorenko G, Lashuel HA. Revisiting the grammar of Tau aggregation and pathology formation: how new insights from brain pathology are shaping how we study and target Tauopathies. Chem Soc Rev. 2022;51(2):513-565. https:\/\/doi.org\/10.1039\/D1CS00127B","DOI":"10.1039\/d1cs00127b"},{"key":"ref75","doi-asserted-by":"publisher","unstructured":"Schaff LR, Grommes C. Primary central nervous system lymphoma. Blood. 2022;140(9):971-979. https:\/\/doi.org\/10.1182\/blood.2020008377","DOI":"10.1182\/blood.2020008377"},{"key":"ref76","doi-asserted-by":"crossref","unstructured":"Ngo VN, Young RM, Schmitz R, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature. 2011;470(7332):115-119. https:\/\/doi.org\/10.1038\/nature09671","DOI":"10.1038\/nature09671"},{"key":"ref77","doi-asserted-by":"publisher","unstructured":"Schaff LR, Grommes C. Update on novel therapeutics for primary CNS lymphoma. Cancers. 2021;13(21):5372. https:\/\/doi.org\/10.3390\/cancers13215372","DOI":"10.3390\/cancers13215372"},{"key":"ref78","doi-asserted-by":"publisher","unstructured":"Goldwirt L, Beccaria K, Ple A, et al. Ibrutinib brain distribution: a preclinical study. Cancer Chemother Pharmacol. 2018;81(4):783-789. https:\/\/doi.org\/10.1007\/s00280-018-3546-3","DOI":"10.1007\/s00280-018-3546-3"},{"key":"ref79","doi-asserted-by":"publisher","unstructured":"Lionakis MS, Dunleavy K, Roschewski M, et al. Inhibition of B cell receptor signaling by Ibrutinib in primary CNS lymphoma. Cancer Cell. 2017;31(6):833-843.e5. https:\/\/doi.org\/10.1016\/j.ccell.2017.04.012","DOI":"10.1016\/j.ccell.2017.04.012"},{"key":"ref80","doi-asserted-by":"publisher","unstructured":"Zhai Y, Zhou X, Wang X. Novel insights into the biomarkers and therapies for primary central nervous system lymphoma. Ther Adv Med Oncol. 2022;14:175883592210937. https:\/\/doi.org\/10.1177\/17588359221093745","DOI":"10.1177\/17588359221093745"},{"key":"ref81","doi-asserted-by":"publisher","unstructured":"Grommes C, Pastore A, Palaskas N, et al. Ibrutinib unmasks critical role of bruton tyrosine kinase in primary CNS lymphoma. Cancer Discovery. 2017;7(9):1018-1029. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-0613","DOI":"10.1158\/2159-8290.cd-17-0613"},{"key":"ref82","doi-asserted-by":"publisher","unstructured":"Soussain C, Choquet S, Blonski M, et al. Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II 'proof-of-concept' iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network. European Journal of Cancer. 2019;117:121-130. https:\/\/doi.org\/10.1016\/j.ejca.2019.05.024","DOI":"10.1016\/j.ejca.2023.04.025"},{"key":"ref83","doi-asserted-by":"publisher","unstructured":"Grommes C, Tang SS, Wolfe J, et al. Phase 1b trial of an ibrutinib-based combination therapy in recurrent\/refractory CNS lymphoma. Blood. 2019;133(5):436-445. https:\/\/doi.org\/10.1182\/blood-2018-09-875732","DOI":"10.1182\/blood-2018-09-875732"},{"key":"ref84","doi-asserted-by":"publisher","unstructured":"Houillier C, Chabrot CM, Moles-Moreau M-P, et al. Rituximab-Lenalidomide-Ibrutinib combination for relapsed\/refractory primary CNS lymphoma: A Case Series of the LOC Network. Neurology. 2021;97(13):628-631. https:\/\/doi.org\/10.1212\/WNL.0000000000012515","DOI":"10.1212\/wnl.0000000000012515"},{"key":"ref85","doi-asserted-by":"publisher","unstructured":"Munakata W, Tobinai K. Tirabrutinib hydrochloride for B-cell lymphomas. Drugs Today. 2021;57(4):277. https:\/\/doi.org\/10.1358\/dot.2021.57.4.3264113","DOI":"10.1358\/dot.2021.57.4.3264113"},{"key":"ref86","doi-asserted-by":"publisher","unstructured":"Okita Y, Kano-Fujiwara R, Nakatsuka S-I, et al. Histological verification of the treatment effect of tirabrutinib for relapsed\/refractory primary central nervous system lymphoma. Exp Hematol Oncol. 2021;10(1):29. https:\/\/doi.org\/10.1186\/s40164-021-00222-5","DOI":"10.1186\/s40164-021-00222-5"},{"key":"ref87","doi-asserted-by":"publisher","unstructured":"Yang C, Cui Y, Ren X, et al. Orelabrutinib combined with Lenalidomide and immunochemotherapy for relapsed\/refractory primary central nervous system lymphoma: a retrospective analysis of case series. Front Oncol. 2022;12:901797. https:\/\/doi.org\/10.3389\/fonc.2022.901797","DOI":"10.3389\/fonc.2022.901797"},{"key":"ref88","doi-asserted-by":"publisher","unstructured":"Yu CG, Bondada V, Iqbal H, et al. Inhibition of Bruton Tyrosine Kinase Reduces Neuroimmune Cascade and Promotes Recovery after Spinal Cord Injury. Int J Mol Sci. 2021;23(1):355. https:\/\/doi.org\/10.3390\/ijms23010355","DOI":"10.3390\/ijms23010355"},{"key":"ref89","doi-asserted-by":"crossref","unstructured":"Liu Y, Huang Z, Zhang T-X, et al. Bruton's tyrosine kinase-bearing B cells and microglia in neuromyelitis optica spectrum disorder. J Neuroinflammation. 2023;20(1):309. https:\/\/doi.org\/10.1186\/s12974-023-02997-2","DOI":"10.1186\/s12974-023-02997-2"},{"key":"ref90","doi-asserted-by":"publisher","unstructured":"Zheng C, Li W, Ali T, et al. Ibrutinib Delays ALS Installation and Increases Survival of SOD1G93A Mice by Modulating PI3K\/mTOR\/Akt Signaling. J Neuroimmune Pharmacol. 2023;18(3):383-396. https:\/\/doi.org\/10.1007\/s11481-023-10068-9","DOI":"10.1007\/s11481-023-10068-9"},{"key":"ref91","doi-asserted-by":"publisher","unstructured":"Li K, Ran B, Wang Y, et al. PLC\u03b32 impacts microglia-related effectors revealing variants and pathways important in Alzheimer's disease. Front Cell Dev Biol. 2022;10:999061. https:\/\/doi.org\/10.3389\/fcell.2022.999061","DOI":"10.3389\/fcell.2022.999061"},{"key":"ref92","doi-asserted-by":"publisher","unstructured":"Vastrad B, Vastrad C. Screening of the key genes and signaling pathways for schizophrenia using bioinformatics and next generation sequencing data analysis [Internet]. 2023 [cited 2024 Dec 20]. Available from: http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2023.10.24.563759. https:\/\/doi.org\/10.1101\/2023.10.24.563759","DOI":"10.1101\/2023.10.24.563759"},{"key":"ref93","doi-asserted-by":"publisher","unstructured":"Roussou IG, Papanikolopoulou K, Savakis C, et al. Drosophila Bruton's tyrosine kinase regulates habituation latency and facilitation in distinct mushroom body neurons. J Neurosci. 2019;39(44):8730-8743. https:\/\/doi.org\/10.1523\/JNEUROSCI.0633-19.2019","DOI":"10.1523\/jneurosci.0633-19.2019"},{"key":"ref94","doi-asserted-by":"publisher","unstructured":"Reich DS, Arnold DL, Vermersch P, et al. Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2021;20(9):729-738. https:\/\/doi.org\/10.1016\/S1474-4422(21)00237-4","DOI":"10.1016\/j.msard.2023.104850"},{"key":"ref95","doi-asserted-by":"publisher","unstructured":"Mali AS, Novotny J. Opioid receptor activation suppresses the neuroinflammatory response by promoting microglial M2 polarization. Mol Cell Neurosci. 2022;121:103744. https:\/\/doi.org\/10.1016\/j.mcn.2022.103744","DOI":"10.1016\/j.mcn.2022.103744"},{"key":"ref96","doi-asserted-by":"publisher","unstructured":"Martin E, Aigrot M-S, Grenningloh R, et al. Bruton's Tyrosine Kinase Inhibition Promotes Myelin Repair. Brain Plast. 2020;5(2):123-133. https:\/\/doi.org\/10.3233\/BPL-200100","DOI":"10.3233\/bpl-200100"}],"container-title":["Physiological Research"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,5,18]],"date-time":"2025-05-18T20:07:35Z","timestamp":1747598855000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.biomed.cas.cz\/physiolres\/pdf\/2025\/74_233.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,30]]},"references-count":97,"URL":"https:\/\/doi.org\/10.33549\/physiolres.935494","relation":{},"ISSN":["1802-9973","0862-8408"],"issn-type":[{"value":"1802-9973","type":"electronic"},{"value":"0862-8408","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,30]]}}}